Drug Trial Radar · NCT07181369
A Phase 1 Study of GTX-B001 in Healthy Subjects and Patients With Chronic Inducible Urticaria
Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
72
Planned (sponsor's estimate)
Start
Oct 6, 2025
Primary completion
Aug 2027
Study completion Aug 2027
Sponsor
- Lead sponsor
- Granular Therapeutics LimitedIndustry
- Sponsor type
- Industry
- First posted
- Sep 18, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a first-in-human study aimed at determining the safety of a single dose of GTX-B001 in healthy participants and in people with chronic inducible urticaria.
Conditions
- Healthy Subjects
- Cold Urticaria
- Symptomatic Dermographism
- Chronic Inducible Urticaria
Interventions
GTX-B001Drug
Single infusion of one of up to five dosages of GTX-B001
Normal SalineDrug
Single infusion of normal saline
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety as assessed by the incidence and severity of adverse events (Parts A and B)Time frame: Day 1 to Day 85
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Charite Universitaetsmedizin Berlin
Berlin, Germany · Recruiting
Charité Research Organization gmbh
Berlin, Germany · Active not recruiting
Dermatologische Praxis
Halle, Germany · Recruiting
Universitaetsklinikum Giessen und Marburg GmbH
Marburg, Germany · Recruiting
Universitatsklinikum Münster
Münster, Germany · Recruiting
Universitaetsklinikum Tübingen
Tübingen, Germany · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.